Review



primary antibodies against apo c3  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Proteintech primary antibodies against apo c3
    Figure 1. Apo <t>C3</t> is abundant in the plasma of patients with AD and deposits in the aorta. A, Heat map results of plasma exosome sequencing in patients with AD (n=20) and normal controls (n=20). B, ELISA results of apo C3 in the plasma of patients with AD (n=20) and NCs (n=20). C, Representative western blot of apo C3 protein in the aortas of patients with AD (n=6) and NCs (n=6). D, Representative immunohistochemistry of apo C3 in the aortas of patients with AD (n=8) and normal controls (n=8). E, Representative immunofluorescence of apo C3 in the aortas of patients with AD (n=9) and normal controls (n=9). F through H, Quantitative protein levels of apo C3 in western blot (C), immunohistochemistry (D), and immunofluorescence (E). Data are expressed as mean±SEM. Bars represent the means, and caps represent the SEM. Statistical comparisons were made using an unpaired t test (B, F through H). A value of P<0.05 was considered significant. The layers of the aorta are denoted as I for intima, M for media, and A for adventitia. AD indicates aortic dissection; apo C3 apolipoprotein C3; α-SMA, α-smooth muscle actin; CD: cluster of differentiation; ENO, enolase; LPL, lipoprotein lipase; MMP, matrix metalloproteinase; NC, normal control; and RBP, retinol-binding protein.
    Primary Antibodies Against Apo C3, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 90 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against apo c3/product/Proteintech
    Average 94 stars, based on 90 article reviews
    primary antibodies against apo c3 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Hepatic Abnormal Secretion of Apolipoprotein C3 Promotes Inflammation in Aortic Dissection"

    Article Title: Hepatic Abnormal Secretion of Apolipoprotein C3 Promotes Inflammation in Aortic Dissection

    Journal: Journal of the American Heart Association

    doi: 10.1161/jaha.124.037172

    Figure 1. Apo C3 is abundant in the plasma of patients with AD and deposits in the aorta. A, Heat map results of plasma exosome sequencing in patients with AD (n=20) and normal controls (n=20). B, ELISA results of apo C3 in the plasma of patients with AD (n=20) and NCs (n=20). C, Representative western blot of apo C3 protein in the aortas of patients with AD (n=6) and NCs (n=6). D, Representative immunohistochemistry of apo C3 in the aortas of patients with AD (n=8) and normal controls (n=8). E, Representative immunofluorescence of apo C3 in the aortas of patients with AD (n=9) and normal controls (n=9). F through H, Quantitative protein levels of apo C3 in western blot (C), immunohistochemistry (D), and immunofluorescence (E). Data are expressed as mean±SEM. Bars represent the means, and caps represent the SEM. Statistical comparisons were made using an unpaired t test (B, F through H). A value of P<0.05 was considered significant. The layers of the aorta are denoted as I for intima, M for media, and A for adventitia. AD indicates aortic dissection; apo C3 apolipoprotein C3; α-SMA, α-smooth muscle actin; CD: cluster of differentiation; ENO, enolase; LPL, lipoprotein lipase; MMP, matrix metalloproteinase; NC, normal control; and RBP, retinol-binding protein.
    Figure Legend Snippet: Figure 1. Apo C3 is abundant in the plasma of patients with AD and deposits in the aorta. A, Heat map results of plasma exosome sequencing in patients with AD (n=20) and normal controls (n=20). B, ELISA results of apo C3 in the plasma of patients with AD (n=20) and NCs (n=20). C, Representative western blot of apo C3 protein in the aortas of patients with AD (n=6) and NCs (n=6). D, Representative immunohistochemistry of apo C3 in the aortas of patients with AD (n=8) and normal controls (n=8). E, Representative immunofluorescence of apo C3 in the aortas of patients with AD (n=9) and normal controls (n=9). F through H, Quantitative protein levels of apo C3 in western blot (C), immunohistochemistry (D), and immunofluorescence (E). Data are expressed as mean±SEM. Bars represent the means, and caps represent the SEM. Statistical comparisons were made using an unpaired t test (B, F through H). A value of P<0.05 was considered significant. The layers of the aorta are denoted as I for intima, M for media, and A for adventitia. AD indicates aortic dissection; apo C3 apolipoprotein C3; α-SMA, α-smooth muscle actin; CD: cluster of differentiation; ENO, enolase; LPL, lipoprotein lipase; MMP, matrix metalloproteinase; NC, normal control; and RBP, retinol-binding protein.

    Techniques Used: Clinical Proteomics, Sequencing, Enzyme-linked Immunosorbent Assay, Western Blot, Immunohistochemistry, Immunofluorescence, Dissection, Control, Binding Assay

    Figure 3. Transcriptome sequencing reveals inhibition of TLR2/NLRP3 pathway activation, M1 macrophage polarization, and MMP release in the aortas of mice after hepatic apo C3 interference. A through E, Results of transcriptome sequencing in the aortas of mice in the BAPN group (n=5) and BAPN+Sh-apo C3 group (n=5). A, Volcano plot. B, Heat map. C, Protein–protein interaction network of apo C3 with differentially expressed genes. D, GO analysis results. E, KEGG analysis results. apo C3 indicates apolipoprotein C3; BAPN, β-aminopropionitrile; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MMP, matrix metalloproteinase; NLRP3, NOD-like receptor pyrin domain containing 3; and TLR2, Toll-like receptor 2.
    Figure Legend Snippet: Figure 3. Transcriptome sequencing reveals inhibition of TLR2/NLRP3 pathway activation, M1 macrophage polarization, and MMP release in the aortas of mice after hepatic apo C3 interference. A through E, Results of transcriptome sequencing in the aortas of mice in the BAPN group (n=5) and BAPN+Sh-apo C3 group (n=5). A, Volcano plot. B, Heat map. C, Protein–protein interaction network of apo C3 with differentially expressed genes. D, GO analysis results. E, KEGG analysis results. apo C3 indicates apolipoprotein C3; BAPN, β-aminopropionitrile; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MMP, matrix metalloproteinase; NLRP3, NOD-like receptor pyrin domain containing 3; and TLR2, Toll-like receptor 2.

    Techniques Used: Sequencing, Inhibition, Activation Assay



    Similar Products

    primary antibodies against apo c3  (Proteintech)
    94
    Proteintech primary antibodies against apo c3
    Figure 1. Apo <t>C3</t> is abundant in the plasma of patients with AD and deposits in the aorta. A, Heat map results of plasma exosome sequencing in patients with AD (n=20) and normal controls (n=20). B, ELISA results of apo C3 in the plasma of patients with AD (n=20) and NCs (n=20). C, Representative western blot of apo C3 protein in the aortas of patients with AD (n=6) and NCs (n=6). D, Representative immunohistochemistry of apo C3 in the aortas of patients with AD (n=8) and normal controls (n=8). E, Representative immunofluorescence of apo C3 in the aortas of patients with AD (n=9) and normal controls (n=9). F through H, Quantitative protein levels of apo C3 in western blot (C), immunohistochemistry (D), and immunofluorescence (E). Data are expressed as mean±SEM. Bars represent the means, and caps represent the SEM. Statistical comparisons were made using an unpaired t test (B, F through H). A value of P<0.05 was considered significant. The layers of the aorta are denoted as I for intima, M for media, and A for adventitia. AD indicates aortic dissection; apo C3 apolipoprotein C3; α-SMA, α-smooth muscle actin; CD: cluster of differentiation; ENO, enolase; LPL, lipoprotein lipase; MMP, matrix metalloproteinase; NC, normal control; and RBP, retinol-binding protein.
    Primary Antibodies Against Apo C3, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against apo c3/product/Proteintech
    Average 94 stars, based on 1 article reviews
    primary antibodies against apo c3 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. Apo C3 is abundant in the plasma of patients with AD and deposits in the aorta. A, Heat map results of plasma exosome sequencing in patients with AD (n=20) and normal controls (n=20). B, ELISA results of apo C3 in the plasma of patients with AD (n=20) and NCs (n=20). C, Representative western blot of apo C3 protein in the aortas of patients with AD (n=6) and NCs (n=6). D, Representative immunohistochemistry of apo C3 in the aortas of patients with AD (n=8) and normal controls (n=8). E, Representative immunofluorescence of apo C3 in the aortas of patients with AD (n=9) and normal controls (n=9). F through H, Quantitative protein levels of apo C3 in western blot (C), immunohistochemistry (D), and immunofluorescence (E). Data are expressed as mean±SEM. Bars represent the means, and caps represent the SEM. Statistical comparisons were made using an unpaired t test (B, F through H). A value of P<0.05 was considered significant. The layers of the aorta are denoted as I for intima, M for media, and A for adventitia. AD indicates aortic dissection; apo C3 apolipoprotein C3; α-SMA, α-smooth muscle actin; CD: cluster of differentiation; ENO, enolase; LPL, lipoprotein lipase; MMP, matrix metalloproteinase; NC, normal control; and RBP, retinol-binding protein.

    Journal: Journal of the American Heart Association

    Article Title: Hepatic Abnormal Secretion of Apolipoprotein C3 Promotes Inflammation in Aortic Dissection

    doi: 10.1161/jaha.124.037172

    Figure Lengend Snippet: Figure 1. Apo C3 is abundant in the plasma of patients with AD and deposits in the aorta. A, Heat map results of plasma exosome sequencing in patients with AD (n=20) and normal controls (n=20). B, ELISA results of apo C3 in the plasma of patients with AD (n=20) and NCs (n=20). C, Representative western blot of apo C3 protein in the aortas of patients with AD (n=6) and NCs (n=6). D, Representative immunohistochemistry of apo C3 in the aortas of patients with AD (n=8) and normal controls (n=8). E, Representative immunofluorescence of apo C3 in the aortas of patients with AD (n=9) and normal controls (n=9). F through H, Quantitative protein levels of apo C3 in western blot (C), immunohistochemistry (D), and immunofluorescence (E). Data are expressed as mean±SEM. Bars represent the means, and caps represent the SEM. Statistical comparisons were made using an unpaired t test (B, F through H). A value of P<0.05 was considered significant. The layers of the aorta are denoted as I for intima, M for media, and A for adventitia. AD indicates aortic dissection; apo C3 apolipoprotein C3; α-SMA, α-smooth muscle actin; CD: cluster of differentiation; ENO, enolase; LPL, lipoprotein lipase; MMP, matrix metalloproteinase; NC, normal control; and RBP, retinol-binding protein.

    Article Snippet: Primary antibodies against apo C3 (1:100; Affinity; DF8054), TLR2 (1:100; Proteintech; 17 236- 1- AP), NLRP3 (1:100; Invitrogen; MA5- 23919), CD86 (1:100, Proteintech; 13 395- 1- AP), INOS (1:100; Invitrogen; PA1- 036), MMP2 (1:100; Proteintech; 10 373- 2- AP), MMP9 (1:100; Proteintech; 10 375- 2- AP), CD68 (1:100; Invitrogen; 14- 0688- 82), F4/80 (1:100 Invitrogen; 14–4801- 82), CD31(1:100; Abcam; ab9498) and α- smooth muscle actin (1:100; Boster; BM4172), were incubated overnight at 4°C.

    Techniques: Clinical Proteomics, Sequencing, Enzyme-linked Immunosorbent Assay, Western Blot, Immunohistochemistry, Immunofluorescence, Dissection, Control, Binding Assay

    Figure 3. Transcriptome sequencing reveals inhibition of TLR2/NLRP3 pathway activation, M1 macrophage polarization, and MMP release in the aortas of mice after hepatic apo C3 interference. A through E, Results of transcriptome sequencing in the aortas of mice in the BAPN group (n=5) and BAPN+Sh-apo C3 group (n=5). A, Volcano plot. B, Heat map. C, Protein–protein interaction network of apo C3 with differentially expressed genes. D, GO analysis results. E, KEGG analysis results. apo C3 indicates apolipoprotein C3; BAPN, β-aminopropionitrile; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MMP, matrix metalloproteinase; NLRP3, NOD-like receptor pyrin domain containing 3; and TLR2, Toll-like receptor 2.

    Journal: Journal of the American Heart Association

    Article Title: Hepatic Abnormal Secretion of Apolipoprotein C3 Promotes Inflammation in Aortic Dissection

    doi: 10.1161/jaha.124.037172

    Figure Lengend Snippet: Figure 3. Transcriptome sequencing reveals inhibition of TLR2/NLRP3 pathway activation, M1 macrophage polarization, and MMP release in the aortas of mice after hepatic apo C3 interference. A through E, Results of transcriptome sequencing in the aortas of mice in the BAPN group (n=5) and BAPN+Sh-apo C3 group (n=5). A, Volcano plot. B, Heat map. C, Protein–protein interaction network of apo C3 with differentially expressed genes. D, GO analysis results. E, KEGG analysis results. apo C3 indicates apolipoprotein C3; BAPN, β-aminopropionitrile; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MMP, matrix metalloproteinase; NLRP3, NOD-like receptor pyrin domain containing 3; and TLR2, Toll-like receptor 2.

    Article Snippet: Primary antibodies against apo C3 (1:100; Affinity; DF8054), TLR2 (1:100; Proteintech; 17 236- 1- AP), NLRP3 (1:100; Invitrogen; MA5- 23919), CD86 (1:100, Proteintech; 13 395- 1- AP), INOS (1:100; Invitrogen; PA1- 036), MMP2 (1:100; Proteintech; 10 373- 2- AP), MMP9 (1:100; Proteintech; 10 375- 2- AP), CD68 (1:100; Invitrogen; 14- 0688- 82), F4/80 (1:100 Invitrogen; 14–4801- 82), CD31(1:100; Abcam; ab9498) and α- smooth muscle actin (1:100; Boster; BM4172), were incubated overnight at 4°C.

    Techniques: Sequencing, Inhibition, Activation Assay